Drug Developement/Delivery
- Overviews of the Antibody-drug conjugates (ADCs)
- ADCs Beyond Cancer: Emerging Therapeutic Potential
- ADC Market 2025: Rising Sales and Growing Phase III Pipelines
- Antibody-Degrader Conjugates (DACs): The Next Evolution of Antibody-Drug Conjugates
- Clinical Development of ADC Drugs Targeting TROP-2
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- Antibody–Drug Conjugates Targeting MUC1
- Global Sales of ADCs in 2023 – UP to 10 Billion
- From ADCs to ABCs: A New Strategy for High-Capacity Targeted Drug Delivery
- siRNA Therapeutics: Current Status & Delivery System